/PRNewswire/ Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced.
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors
Expands company s financial expertise during time of growth in advance of commercial launch
News provided by
Share this article
Share this article
LISLE, Ill., March 2, 2021 /PRNewswire/ Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of Directors. Mr. Dearen currently serves as the President and Chief Financial Officer of Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company he helped take public in 2018 with sales in 2020 of over $111 million and a current market capitalization of $2 billion. Mr. Dearen joins the Endotronix Board as an Independent Director and will serve as Chair of the Audit Committee.